GU Cancers 2021 | Immune checkpoint inhibitors and sitravatinib in bladder cancer

Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares her insights into the results of clinical trials evaluating the efficacy of the tyrosine kinase inhibitor, sitravatinib (sitra), in combination with the immune checkpoint inhibitors (ICI) nivolumab (nivo) and ipilimumab (ipi). There is evidence of early clinical activity in patients treated with sitra post-chemotherapy and ICI treatment. The combination of sitra and nivo showed response rates in approximately 30% of patients previously resistant to ICI regimens. An enhanced immune response could be seen in patients with renal cell cancer and urothelial cancer if treated with sitra + nivo + ipi. This interview took place during the 2021 Genitourinary Cancers Symposium.